Multiple sclerosis is one of the most common causes of chronic neurological disability beginning in early to middle adult life. Multiple sclerosis is idiopathic in nature, yet increasing correlative evidence supports a strong association between one's genetic predisposition, the environment and the immune system.
Symptoms of multiple sclerosis have primarily been shown to result from a disruption in the integrity of myelinated tracts within the white matter of the central nervous system. However, recent research has also highlighted the hitherto underappreciated involvement of gray matter in multiple sclerosis disease pathophysiology, which may be especially relevant when considering the accumulation of irreversible damage and progressive disability.
This review aims at providing a comprehensive overview of the interplay between inflammation, glial/neuronal damage and regeneration throughout the course of multiple sclerosis via the analysis of both white and gray matter lesional pathology. Further, we describe the common pathological mechanisms underlying both relapsing and progressive forms of multiple sclerosis, and analyze how current (as well as future) treatments may interact and/or interfere with its pathology.
Understanding the putative mechanisms that drive disease pathogenesis will be key in helping to develop effective therapeutic strategies to prevent, mitigate, and treat the diverse morbidities associated with multiple sclerosis. ß 2015 Elsevier Ltd. All rights reserved.
Abbreviations: APC, antigen presenting cell; BBB, blood-brain barrier; CCR, CC chemokine receptor; CIS, clinical isolated syndrome; CNPase, 2 0 ,3 0 -cyclic-nucleotide 3 0 -phosphodiesterase; CNS, central nervous system; CNTF, ciliary neurotrophic factor; CSF, cerebrospinal fluid; DMDs, disease-modifying drugs; EBV, Epstein-Barr virus; FDC, follicular dendritic cell; FOXP3, factor forkhead box P3; GM, grey matter; HLA, human leukocyte antigen; HSC, hematopoietic stem cell; ICAM, intercellular adhesion molecule; IFN, interferon; Ig, immunoglobulin; IL, interleukin; iNSC, induced neural stem cell; iPSC, induced pluripotent stem cell; LFA, leukocyte function-associated antigen; MAG, myelin-associated glycoprotein; MHC, major histocompatibility complex; MOG, myelin oligodendrocyte glycoprotein; MMP, matrix metalloproteinases; MRI, magnetic resonance imaging; MS, multiple sclerosis; MSC, mesenchymal stem cell; NSC, neural stem cell; OPC, oligodendrocytes precursor cell; PET, positron emission tomography; PML, progressive multifocal leukoencephalopathy; PP, primary progressive; RR, relapsing-remitting; RXR g, retinoid X receptor g; SP, secondary progressive; TGF, transforming growth factor; Th, T helper cell; TNF, tumor necrosis factor; Treg, T regulatory cell; VCAM, vascular cell adhesion molecule; VLA, very late antigen; WM, white matter.
